Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects.
Sign Up to like & getrecommendations! Published in 2023 at "Epigenomics"
DOI: 10.2217/epi-2022-0320
Abstract: EZH2 is an epigenetic regulator that methylates lysine 27 on histone H3 (H3K27) and is closely related to the development and metastasis of tumors. It often shows gain-of-function mutations in hematological tumors, while it is… read more here.
Keywords: therapies solid; combining ezh2; tumors choices; inhibitors therapies ... See more keywords
Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15051412
Abstract: Simple Summary Cancer treatments have significantly changed with the introduction of immunotherapy. Recently, the development of new agents that harness the redirection of T-cells against cancer is rapidly emerging in multiple tumor types. Since bispecific… read more here.
Keywords: therapies solid; prostate cancer; solid tumors; bispecific cell ... See more keywords